Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
Sandra E. Ghayad(Inserm), Pascale A. Cohen(Lyon 1 Université), Julie A. Vendrell(Inserm), Isabelle Treilleux(Centre Léon Bérard), Rosette Lidereau(Inserm), Charles Dumontet(Centre de Recherche en Cancérologie de Lyon), Frédérique Spyratos(Hôpital René Huguenin), Ivan Bièche(Centre National de la Recherche Scientifique)
Cited by 70
Related Papers
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
|The Lancet Oncology|2014|410
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
|Nature Genetics|2015|375
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
|Endocrine Reviews|2011|302